Glaxosmithkline Pharmaceuticals Ltd vs Windlas Biotech Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 14, 2026

Key Highlights

The Latest Trading Price of Glaxosmithkline Pharmaceuticals Ltd is ₹ 2417 as of 14 May 15:30 . The P/E Ratio of Glaxosmithkline Pharmaceuticals Ltd changed from 68.1 on March 2021 to 52.5 on March 2025 . This represents a CAGR of -5.07% over 5 yearsThe P/E Ratio of Windlas Biotech Ltd changed from 12 on March 2022 to 35.8 on March 2025 . This represents a CAGR of 31.42% over 4 years The Market Cap of Glaxosmithkline Pharmaceuticals Ltd changed from ₹ 24401 crore on March 2021 to ₹ 48743 crore on March 2025 . This represents a CAGR of 14.84% over 5 yearsThe Market Cap of Windlas Biotech Ltd changed from ₹ 457.9 crore on March 2022 to ₹ 2176 crore on March 2025 . This represents a CAGR of 47.65% over 4 years The revenue of Glaxosmithkline Pharmaceuticals Ltd for the Mar '26 is ₹ 1031 crore as compare to the Dec '25 revenue of ₹ 1091 crore. This represent the decline of -5.51% The revenue of Windlas Biotech Ltd for the Mar '26 is ₹ 0 crore as compare to the Dec '25 revenue of ₹ 237.67 crore. This represent the decline of -100% The ebitda of Glaxosmithkline Pharmaceuticals Ltd for the Mar '26 is ₹ 386.88 crore as compare to the Dec '25 ebitda of ₹ 421.44 crore. This represent the decline of -8.2% The ebitda of Windlas Biotech Ltd for the Mar '26 is ₹ 0 crore as compare to the Dec '25 ebitda of ₹ 28.95 crore. This represent the decline of -100% The net profit of Glaxosmithkline Pharmaceuticals Ltd changed from ₹ 182.33 crore to ₹ 277.86 crore over 8 quarters. This represents a CAGR of 23.45% The net profit of Windlas Biotech Ltd changed from ₹ 13.48 crore to ₹ 0 crore over 8 quarters. This represents a CAGR of -100.00% The Dividend Payout of Glaxosmithkline Pharmaceuticals Ltd changed from 142.13 % on March 2021 to 99.54 % on March 2025 . This represents a CAGR of -6.88% over 5 yearsThe Dividend Payout of Windlas Biotech Ltd changed from 19.79 % on March 2022 to 20.04 % on March 2025 . This represents a CAGR of 0.31% over 4 years .

About Glaxosmithkline Pharmaceuticals Ltd

GlaxoSmithKline Pharmaceuticals Limited was erstwhile incorporated as 'Glindia Limited' in November, 1924.
The Company' s name was changed to Glaxo (India) Limited' from Glindia Limited in year 1987 and further to 'GlaxoSmithKline Pharmaceuticals Limited' from Glaxo (India) Limited effective from October 22, 2001. GlaxoSmithKline Pharmaceuticals Limited is a subsidiary of UK-based GSK Plc., a global biopharma company to unite science, technology and talent to get ahead of disease together.
The Company is headquartered in Mumbai and it has six branch offices, one manufacturing facility at Nashik in Maharashtra, 20 contract manufacturing organisations (CMOs) with regional and sales hubs across India.
The Company is engaged interalia, in the business of manufacturing, distributing and trading in pharmaceuticals.

About Windlas Biotech Ltd

Windlas Biotech Limited, formerly known as Windlas Biotech Private Limited was incorporated in 2001.
The Company got converted from a Private Limited to a Public Limited Company and the name of the Company was changed to Windlas Biotech Limited'.
A fresh Certificate of Incorporation dated April 15, 2021, granted by the Registrar of Companies, Uttarakhand at Dehradun. The Company is engaged in manufacturing and trading of pharmaceutical products.
Their manufacturing plants are located at Dehradun in Uttarakhand.
It has three distinct strategic business verticals (SBVs) mainly comprising of CDMO services and products; domestic trade generics and over-the-counter (OTC) brands; and exports. The Company commenced operations at Dehradun Plant -IV in 2010.

FAQs for the comparison of Glaxosmithkline Pharmaceuticals Ltd and Windlas Biotech Ltd

Which company has a larger market capitalization, Glaxosmithkline Pharmaceuticals Ltd or Windlas Biotech Ltd?

Market cap of Glaxosmithkline Pharmaceuticals Ltd is 40,958 Cr while Market cap of Windlas Biotech Ltd is 1,611 Cr

What are the key factors driving the stock performance of Glaxosmithkline Pharmaceuticals Ltd and Windlas Biotech Ltd?

The stock performance of Glaxosmithkline Pharmaceuticals Ltd and Windlas Biotech Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Glaxosmithkline Pharmaceuticals Ltd and Windlas Biotech Ltd?

As of May 14, 2026, the Glaxosmithkline Pharmaceuticals Ltd stock price is INR ₹2417.75. On the other hand, Windlas Biotech Ltd stock price is INR ₹763.55.

How do dividend payouts of Glaxosmithkline Pharmaceuticals Ltd and Windlas Biotech Ltd compare?

To compare the dividend payouts of Glaxosmithkline Pharmaceuticals Ltd and Windlas Biotech Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.